AstraZeneca invests USD 2 billion in Summit. AstraZeneca stock falls 1.24 percent.
Published on 10/01/2026 at 09:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca (ISIN GB0009895292) was trading at EUR 141.48 at Lang & Schwarz on October 1, 2026 at 9:12 a.m. CEST, down 1.24 percent from the prior close of EUR 143.25. As Yahoo Finance reported on September 28, 2026, Summit Therapeutics said AstraZeneca had agreed to invest USD 2 billion and enter a clinical collaboration.
Revenue growth meets patent pressure
In the second quarter of 2026, AstraZeneca generated USD 15.38 billion in revenue, up 6.40 percent from the same quarter a year earlier, according to MarketBeat. The comparison shows solid top-line expansion, but it also leaves the composition of growth important for investors.
For the first half of 2026, Oncology revenue increased 15.00 percent, while BioPharmaceuticals revenue fell 5.00 percent, according to ScanX. The split makes the Summit investment strategically relevant because AstraZeneca is directing capital toward pipeline assets while established products face generic competition.
Analysts keep a divided view
MarketBeat reported on September 29, 2026 that Deutsche Bank reaffirmed a Hold rating for AstraZeneca, while six analysts rated the stock Buy and one rated it Hold. That split places the USD 2 billion commitment beside a measurable debate over how quickly pipeline growth can offset pressure on older medicines.
October results set the next test
AstraZeneca's official results calendar lists its H1 and second-quarter 2026 announcement on July 27, 2026, with the next earnings release scheduled for October 30, 2026, according to AstraZeneca and Zacks. The October report will provide the next quantified check on revenue growth, Oncology momentum and the impact of patent expiries.
Stock falls as valuation debate continues
AstraZeneca's market capitalization was USD 250.4 billion as of September 30, 2026. The Lang & Schwarz quote of EUR 141.48 was down 1.24 percent versus the EUR 143.25 prior close on October 1, 2026 at 9:12 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.
AstraZeneca stock facts
- Company: AstraZeneca PLC
- ISIN: GB0009895292
- Ticker: AZN
- Primary exchange: London Stock Exchange
- Price Lang & Schwarz as of October 1, 2026 at 9:12 a.m. CEST: EUR 141.48
- Change versus prior close: minus 1.24 percent
- Prior close Lang & Schwarz September 30, 2026: EUR 143.25
- Market capitalization: USD 250.4 billion as of September 30, 2026
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Index membership: FTSE 100
- Next earnings date: October 30, 2026
